Karen M. Anderson Sells 10,624 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 10,624 shares of the stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $17.32, for a total transaction of $184,007.68. Following the sale, the insider now owns 71,525 shares of the company’s stock, valued at approximately $1,238,813. This represents a 12.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock opened at $16.51 on Thursday. Centessa Pharmaceuticals plc has a 12 month low of $6.65 and a 12 month high of $18.97. The firm has a market capitalization of $2.18 billion, a P/E ratio of -10.79 and a beta of 1.52. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The business has a fifty day simple moving average of $16.58 and a two-hundred day simple moving average of $13.49.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. On average, equities analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CNTA. BMO Capital Markets increased their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. B. Riley started coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 price target for the company. Jefferies Financial Group boosted their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Guggenheim raised their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Finally, Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $25.83.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds have recently made changes to their positions in CNTA. Mirae Asset Global Investments Co. Ltd. raised its stake in Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after buying an additional 826 shares during the last quarter. Atria Investments Inc raised its position in shares of Centessa Pharmaceuticals by 7.0% in the 3rd quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock worth $274,000 after purchasing an additional 1,116 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares during the last quarter. Quarry LP boosted its stake in Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after purchasing an additional 3,108 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Centessa Pharmaceuticals by 99.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock valued at $217,000 after purchasing an additional 6,785 shares during the last quarter. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.